V5514
Anti-Vasopressin V2 Receptor antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
human
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 3 μg/mL using human kidney
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Quality Level
Gene Information
human ... AVPR2(554)
mouse ... Avpr2(12000)
rat ... Avpr2(25108)
Immunogen
Synthetic peptide corresponding to the N-termal extracellular domain of human vasopressin V2 receptor. The immunizing peptide has 67% homology with the rat and mouse gene.
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunohistochemistry (1 paper)
Immunohistochemistry (1 paper)
Biochem/physiol Actions
Vasopressin V2 receptor is a G-protein-coupled receptor that binds to the peptide hormone arginine vasopressin produced by posterior pituitary gland. The V2 receptor stimulates the production of cyclic AMP, controls the water reabsorption and salt balance by the kidneys. Antagonists to the V2 receptor have applications in the treatment of congestive heart failure, hypertension, hyponatremia and excessive water retention.
Physical form
Solution in phosphate buffered saline containing 0.1% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Natasha Tatiana Sobol et al.
Experimental and therapeutic medicine, 21(6), 566-566 (2021-04-15)
Osteosarcoma is the most prevalent primary bone malignancy. Due to its high aggressiveness, novel treatment strategies are urgently required to improve survival of patients with osteosarcoma, especially those with advanced disease. Desmopressin (dDAVP) is a widely used blood-saving agent that
Juan Garona et al.
Clinical & experimental metastasis, 33(6), 589-600 (2016-05-06)
[V(4)Q(5)]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V(4)Q(5)]dDAVP inhibits angiogenesis and metastatic progression
Shuai Mu et al.
Molecules (Basel, Switzerland), 19(2), 2694-2706 (2014-02-26)
Twenty-one non-peptide substituted desloratadine class compounds were synthesized as novel arginine vasopressin receptor antagonists from desloratadine via successive acylation, reduction and acylation reactions. Their structures were characterized by 1H-NMR and HRMS, their biological activity was evaluated by in vitro and
Abeda Jamadar et al.
International journal of molecular sciences, 23(14) (2022-07-28)
Vasopressin type-2 receptor (V2R) is ectopically expressed and plays a pathogenic role in clear cell renal cell carcinoma (ccRCC) tumor cells. Here we examined how V2R signaling within human ccRCC tumor cells (Caki1 cells) stimulates stromal cancer-associated fibroblasts (CAFs). We
[Human recombinant alpha-2b interferon (Introna). Intralesional treatment of therapy-resistant condylomata acuminata].
C S Petersen et al.
Ugeskrift for laeger, 149(24), 1594-1595 (1987-06-08)
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持